CareDx, Inc ("CareDx") announced on 8 April 2016 that the company completes its public offer to the shareholders of Allenex AB (publ), ("Allenex"). After completion of the offer, CareDx holds approximately 98.3 percent of the shares of Allenex and has notified Allenex’ board of directors that CareDx has resolved to initiate compulsory acquisition proceedings regarding the remaining shares.

In light of the above, Allenex’ board of directors does not consider it motivated for Allenex to remain a listed company and has therefore decided to apply for de-listing of the Allenex share from Nasdaq Stockholm. The last day of trading in the Allenex share will be announced as soon as a notification thereof has been received from Nasdaq Stockholm.

For more information please contact:
Anders Karlsson, CEO Allenex AB, and ph.: +4670-918 00 10, e-mail:

Allenex AB discloses the information provided herein pursuant to the Securities Markets Act and /or the Financial Instruments Trading Act. The information was submitted for publication on May 20, 2016, at 08:00 CET.  Allenex is a life science-company that develops, manufacture, market and sell products for safer transplants of organs and bone marrow on the global market. Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 57 persons are employed in the Allenex group.


About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See for more information.


Documents & Links